Abstract: Dry eye disease (DED) remains a therapeutic challenge, particularly in refractory cases. While autologous serum eye drops (ASED) offer short-term benefits, data on their long-term efficacy are scarce. This retrospective longitudinal study evaluated patients treated with ASED for at least three years, with follow-ups at three time points (T1, T2 and T3). Our findings demonstrate that most patients (65.5% at T1, 60% at T2, 65.5% at T3), exhibit a robust and sustained response to ASED therapy over the years, suggesting the potential to identify a responder profile based on early treatment outcomes. Larger-scale studies are needed to clarify the factors underlying this profile, which could ultimately guide personalized therapeutic strategies for DED. Keywords: dry eye disease, autologous serum eye drop, long-term outcomes, ocular surface disease
Velier et al. (Wed,) studied this question.